Suppliers and packagers for cetrotide

cetrotide

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Emd Serono Inc	CETROTIDE	cetrorelix acetate	POWDER;SUBCUTANEOUS	021197	NDA	EMD Serono, Inc.	44087-1225-1	1 KIT in 1 CARTON (44087-1225-1) * 1 mL in 1 VIAL, GLASS * 1 mL in 1 SYRINGE, GLASS	2000-08-11

CETROTIDE Suppliers: Who Makes Cetrotide (Cetrorelix) for Fertility Indications, and What Are the Key Supply and IP Constraints?

Last updated: May 27, 2026

Executive summary: Cetrotide (cetrorelix) is a GnRH antagonist used for fertility treatment. The supply chain is dominated by the original EU/US rights holder for the brand and its contracted manufacturers for the drug substance and finished dose. Practical “supplier” decisions in procurement usually map to (1) the marketing authorization holder (MAH) on the prescribing label for the target market, (2) the contracted sterile injectables manufacturer(s) producing the lyophilized powder or solution strength offered in that market, and (3) any authorized distributors supplying that specific presentation.

No jurisdiction- or presentation-specific supplier list can be produced from the information provided. If you need a supplier map (MAH label-to-manufacturer-of-record, by country and strength), the answer must be derived from the actual product label and regulatory product dossier data (EMA/FDA product pages, and MAH labeling/SmPC package insert manufacturer fields).

Who are the commercial suppliers of Cetrotide (cetrorelix) by country?

Featured snippet answer: Cetrotide is supplied by the company that holds the marketing authorization for the specific country and by distributors authorized to sell that labeled presentation in that market. Manufacturer-of-record for the injectable product is typically listed in the package leaflet as the manufacturer of the finished dosage form.

What to treat as “suppliers” for Cetrotide procurement

1. MAH (marketing authorization holder) for the target jurisdiction (EU member states differ by MAH and product labeling).
2. Manufacturer of the finished product (sterile injectables manufacturing site listed on the leaflet/label).
3. Authorized wholesalers/distributors that source the labeled product from the MAH/importer and sell to hospitals and fertility clinics.
4. Drug substance supplier (cetrorelix active pharmaceutical ingredient, API), often not visible to end users unless disclosed in regulatory submissions.

Why “supplier” lists differ by presentation

Cetrotide can be marketed as different pack sizes and vial strengths (including lyophilized powder for reconstitution and ready-to-use presentations depending on jurisdiction). Each presentation can have a different manufacturer-of-record.

What patents protect cetrorelix (Cetrotide) and how does that affect supply?

Featured snippet answer: Cetrorelix is protected by a patchwork of primary active ingredient patents and secondary patents on formulations, manufacturing, and use. Active ingredient protection and any downstream formulation or method-of-use exclusivity constrain generic and biosimilar-style substitution, keeping supply concentrated among authorized brand holders and contract manufacturers.

Patent estate components that matter for supply

• API synthesis process patents that affect the cost and feasibility of non-infringing API manufacture.
• Sterile formulation and reconstitution patents that affect the excipient system and manufacturing controls.
• Method-of-use patents for specific fertility protocols or dosing schedules.
• Regulatory exclusivities (when applicable) and patent listings that support enforcement.

How patent status changes the generic launch path

When Orange Book-style or comparable patent listings are enforced via FDA/Paragraph IV or EU patent mechanisms, supply remains dominated by the brand and authorized manufacture. When patent barriers clear, additional suppliers can enter via generic or authorized brand-to-generic switches.

What is the Orange Book status of Cetrotide (cetrorelix) and what generic entry risks exist?

Featured snippet answer: A complete Orange Book-style status requires the exact FDA application listing for cetrorelix/cetrorelix acetate products in the US and the specific NDC for the marketed strength and dosage form. That data is not present in the prompt, so a precise listing of FDA patent codes and expiration dates cannot be produced.

What “generic entry” usually requires in practice

• ANDA approval pathway for small molecules (where an ANDA is feasible).
• Demonstration of bioequivalence to the reference listed drug.
• Freedom-to-operate analysis against the listed patents tied to that NDA reference product.
• Supply qualification of sterile injectable manufacturing facilities and process validation.

Which companies manufacture cetrorelix sterile injectables under contract?

Featured snippet answer: Contract manufacturing for Cetrotide is typically executed by sterile injectables specialists, but the exact sites and contract relationships must be taken from the manufacturer-of-record listed in the product leaflet for the specific country and presentation.

What to extract from regulatory labels for manufacturer-of-record

• Finished dosage manufacturer name and address.
• Site responsible for filling and finishing (sterile process).
• Any separate API manufacturer listed for drug substance.

Why API and finished dose can have different “suppliers”

The API supplier may be a different company and site than the finished dose manufacturer. Procurement teams often need both for quality agreements and auditing.

How long do supply constraints last if Cetrotide is impacted by manufacturing or regulatory actions?

Featured snippet answer: Supply durability depends on (1) the number of qualified manufacturing sites listed for the product, (2) whether the MAH uses single-site sterility manufacturing, and (3) whether there are alternate pack presentations. Without a country-specific label and manufacturer list, lead-time and redundancy cannot be quantified.

Key supply disruption triggers in sterile injectables

• Sterile filtration or aseptic fill-finish line outages
• Lyophilization capacity and condenser performance limits
• Batch record deviations leading to lot holds
• Quality system actions at the manufacturing site

How does Cetrotide compare with other GnRH antagonist suppliers (e.g., ganirelix) on sourcing?

Featured snippet answer: GnRH antagonist sourcing risk often shifts by molecule and country. If Cetrotide faces localized shortages, clinicians may be offered alternative GnRH antagonists (such as ganirelix) depending on protocol and availability, but any substitution requires clinical and regulatory alignment.

Procurement comparison angles

• Number of MAHs and authorized distributors per country
• Presence of generics or additional branded alternatives
• Sterile injectable capacity coverage across multiple sites

Key regulatory sourcing artifacts used to identify Cetrotide suppliers

Featured snippet answer: The most reliable sourcing “truth” is the package leaflet and the regulatory product listing for the exact NDC (US) or exact product in the EU/UK. These documents disclose manufacturer-of-record and MAH.

Documents that typically show supplier details

• EU SmPC and patient leaflet: manufacturer-of-finished product
• EMA EPAR page (brand, MAH, and sometimes manufacturing details)
• FDA label for the specific NDC: applicant/labeler and manufacturing info
• National registries (UK MHRA, member state product databases)

Key Takeaways

• “Suppliers” for Cetrotide procurement should be defined as MAH, manufacturer-of-record for the finished sterile dose, and authorized distributors in the target country.
• A supplier list cannot be generated from the prompt alone without the specific Cetrotide presentation and jurisdiction label data that states the manufacturer-of-record.
• Patent and regulatory status constrain generic entry and keep supply concentrated with the MAH and contract manufacturing ecosystem until barriers expire or are cleared.

FAQs

1. What’s the difference between the Cetrotide labeler and the manufacturer-of-record?
   The labeler is the marketing entity on the label, while the manufacturer-of-record is the site responsible for producing the finished sterile dosage form.

2. How do I identify the correct Cetrotide supplier for my country and strength?
   Use the package leaflet and regulatory product listing for the exact strength and dosage form sold in that market.

3. Does Cetrotide sourcing differ between lyophilized and reconstituted presentations?
   Yes. Different presentations can be produced by different sites and can have different distribution networks.

4. Can procurement switch from Cetrotide to another GnRH antagonist during shortages?
   Substitution is possible in clinical practice depending on protocol and regulatory guidance, but procurement feasibility depends on local availability and procurement approvals.

5. What supply risk is highest for sterile injectables like Cetrotide?
   Single-site aseptic fill-finish dependence and lyophilization capacity limits are common high-risk points.

References

1. European Medicines Agency (EMA). Cetrotide (cetrorelix) product information and EPAR materials.
2. U.S. FDA. Orange Book database entries for cetrorelix/cetrorelix acetate products and related labels.
3. EMA and national member-state product leaflets for Cetrotide (manufacturer-of-record sections).